Published mark
LB PHARMACEUTICALS INC
NASDAQ: LBRX. Canonical company identity and public leadership record.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:9169fd39-6d9e-46a0-9224-a2bf4b7df7bc
- SEC CIK
- 0001691082
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 27, 2026
- Newest evidence
- Apr 23, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Not published
- Chair
- Not published
- Independent
- 7 / 88 directors published
- Published claims
- 242 distinct sources
- Evidence records
- 30 pinned
- Source conflicts
- 0None open
Built from 2 distinct sources and 3 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
DIRECTOR APPOINTED
Robert A. Lenz, M.D., Ph.D. seat on LB PHARMACEUTICALS INC, effective 2026-01-01.
EffectiveEffective Jan 1, 2026E2
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Board of directors
Evidence8 directors published. 7 of 8 with a published determination are independent.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Heather Turner | Not independent | 2024 | None published | Source reportedE2 |
| Ran Nussbaum | Independent | 2023 | Nominating and Governance | Source reportedE2 |
| Rebecca Luse | Independent | 2023 | Nominating and Governance, chairNominating and Governance · Chair | Source reportedE2 |
| Rekha Hemrajani | Independent | 2025 | Audit, chairAudit · Chair; CompensationCompensation | Source reportedE2 |
| Robert A. Lenz, M.D., Ph.D. | Independent | 2026 | None published | Source reportedE2 |
| Robert R. Ruffolo, Jr., Ph.D., D.Sc., D.Eng., F.C.P.P. | Independent | 2019 | None published | Source reportedE2 |
| Scott Garland | Independent | 2024 | AuditAudit; Compensation · ChairCompensation, chair | Source reportedE2 |
| William Kane | Independent | 2025 | Compensation | Source reportedE2 |
| Zachary Prensky | Not independent | Not published | Nominating and Governance | Source reportedE2 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit | Rekha Hemrajani | Rekha Hemrajani, Scott Garland | Not described in the published record |
| Audit · Chair; Compensation | Not published | Rekha Hemrajani | Not described in the published record |
| Audit; Compensation · Chair | Not published | Scott Garland | Not described in the published record |
| Compensation | Scott Garland | Scott Garland, Rekha Hemrajani, William Kane | Not described in the published record |
| Nominating and Governance | Rebecca Luse | Rebecca Luse, Ran Nussbaum, Zachary Prensky | Not described in the published record |
| Nominating and Governance · Chair | Not published | Rebecca Luse | Not described in the published record |
Committee RecordAudit: Chair Rekha Hemrajani; Members Rekha Hemrajani (Chair); Scott Garland
Committee AppointmentRekha Hemrajani: chair, Audit
Committee AppointmentScott Garland: member, Audit
Committee RecordCompensation: Chair Scott Garland; Members Scott Garland (Chair); Rekha Hemrajani; William Kane
Committee AppointmentScott Garland: chair, Compensation
Committee AppointmentRekha Hemrajani: member, Compensation
Committee AppointmentWilliam Kane: member, Compensation
Committee RecordNominating and Governance: Chair Rebecca Luse; Members Rebecca Luse (Chair); Ran Nussbaum; Zachary Prensky
Committee AppointmentRebecca Luse: chair, Nominating and Governance
Committee AppointmentRan Nussbaum: member, Nominating and Governance
Committee AppointmentZachary Prensky: member, Nominating and Governance
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceSecurity ListingLBRX (NASDAQ)
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 27, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameLB PHARMACEUTICALS INC
Entity StatusPublic listing published
Published FactUS
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- LeadershipNot reviewed. Executive leadership carries operating authority.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Heather TurnerDirectorcompany:9169fd39-6d9e-46a0-9224-a2bf4b7df7bc:leadership_role:5
- Ran NussbaumDirectorcompany:9169fd39-6d9e-46a0-9224-a2bf4b7df7bc:leadership_role:6
- Rebecca LuseDirectorcompany:9169fd39-6d9e-46a0-9224-a2bf4b7df7bc:leadership_role:7
- Rekha HemrajaniDirectorcompany:9169fd39-6d9e-46a0-9224-a2bf4b7df7bc:leadership_role:8
- Robert A. Lenz, M.D., Ph.D.Directorcompany:9169fd39-6d9e-46a0-9224-a2bf4b7df7bc:leadership_role:9
- company:9169fd39-6d9e-46a0-9224-a2bf4b7df7bc:leadership_role:10
- Scott GarlandDirectorcompany:9169fd39-6d9e-46a0-9224-a2bf4b7df7bc:leadership_role:11
- William KaneDirectorcompany:9169fd39-6d9e-46a0-9224-a2bf4b7df7bc:leadership_role:12
- Zachary PrenskyDirectorcompany:9169fd39-6d9e-46a0-9224-a2bf4b7df7bc:leadership_role:13
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 3 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 27, 2026. Cited by 4 Claims.
- E2sec proxy. Published Apr 23, 2026. Retrieved Apr 24, 2026. Cited by 9 Claims.
- E3board_seats. board seats. Cited by 11 Claims.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 27, 2026- Robert A. Lenz, M.D., Ph.D. seat on LB PHARMACEUTICALS INC, effective 2026-01-01.
- Rekha Hemrajani seat on LB PHARMACEUTICALS INC, effective 2025-01-01.
- William Kane seat on LB PHARMACEUTICALS INC, effective 2025-01-01.
- Audit · Chair; Compensation committee of LB PHARMACEUTICALS INC, effective 2025-01-01.
- Rekha Hemrajani member of Audit · Chair; Compensation, effective 2025-01-01.
- Heather Turner seat on LB PHARMACEUTICALS INC, effective 2024-01-01.
- Scott Garland seat on LB PHARMACEUTICALS INC, effective 2024-01-01.
- Audit; Compensation · Chair committee of LB PHARMACEUTICALS INC, effective 2024-01-01.
- Scott Garland member of Audit; Compensation · Chair, effective 2024-01-01.
- Ran Nussbaum seat on LB PHARMACEUTICALS INC, effective 2023-01-01.
- Rebecca Luse seat on LB PHARMACEUTICALS INC, effective 2023-01-01.
- Ran Nussbaum member of Nominating and Governance, effective 2023-01-01.
- Nominating and Governance · Chair committee of LB PHARMACEUTICALS INC, effective 2023-01-01.
- Rebecca Luse member of Nominating and Governance · Chair, effective 2023-01-01.
- Robert R. Ruffolo, Jr., Ph.D., D.Sc., D.Eng., F.C.P.P. seat on LB PHARMACEUTICALS INC, effective 2019-01-01.